Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug
J&J and biotech partner Protagonist Therapeutics claimed a Phase IIb win in plaque psoriasis Tuesday morning. But near-term plans for the drug remain murky.
The study, looking at an oral IL-23 drug called JNJ-2113, hit its primary endpoint in adults with moderate-to-severe plaque psoriasis, the companies said. Researchers saw more patients who took the drug achieve PASI-75, or at least 75% improvement in skin lesions, by a statistically significant margin compared to placebo in all five treatment cohorts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.